(7-dimethylamino-phenothiazin-3-ylidene)-methyl-amine | 93856-40-7

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: (7-dimethylamino-phenothiazin-3-ylidene)-methyl-amine
• 英文别名: 3-dimethylamino-7-methylamino-phenothiazinylium-betaine；3-Dimethylamino-7-methylamino-phenothiazinylium-betain；Azure；azure-B base；azure-I base
• CAS: 93856-40-7
• 化学式: C₁₅H₁₅N₃S
• 分子量: 269.37
• InChiKey: KKGWEPLBCABCDN-MHWRWJLKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.0
• 重原子数：
  19.0
• 可旋转键数：
  1.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  28.49
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  (7-dimethylamino-phenothiazin-3-ylidene)-methyl-amine 、 水 生成 azure A
  参考文献：
  名称：

  ALPHA-NAPHTHYLISOCYANATE AS A REAGENT FOR ALCOHOLS

  摘要：

  DOI：

  10.1021/ja01414a032

文献信息

• DERIVES DE DIAMINO PHENOTHIAZINE ET COMPOSITION COMPORTANT DES DERIVES DE DIAMINO PHENOTHIAZINE
  申请人：Galey, Laurent

  公开号：EP1311498A1

  公开（公告）日：2003-05-21
• NEUROFIBRILLARY LABELS
  申请人：WisTa Laboratories Ltd.

  公开号：EP1421389B1

  公开（公告）日：2012-05-02
• Inhibition of tau-tau-association
  申请人：Wischik Michel Claude

  公开号：US20070191352A1

  公开（公告）日：2007-08-16

  A composition and use thereof for the prophylaxis or treatment of Alzheimer's disease, motor neurone disease, Lewy body disease, Pick's disease or progressive supranuclear palsy. The composition includes an agent which modulates or inhibits tau-tau association and which does not inhibit tau-tubulin binding. In the method the agent is administered to an individual in order to achieve the desired therapeutic effect. Preferably the agent which is administered is a phenothiazine compound.
• Materials and methods relating to protein aggregation in neurodegenerative disease
  申请人：Wischik Claude Michel

  公开号：US20080207604A1

  公开（公告）日：2008-08-28

  The present invention relates to methods for the detection of substances capable of modulating or inhibiting pathological tau-tau protein association. The methods of the present invention are particularly useful in screening substances for the prophylaxis and treatment of Alzheiemer's disease.
• Neurofibrillary labels
  申请人：Wischik Claude Michel

  公开号：US20080219929A1

  公开（公告）日：2008-09-11

  A method for determining the Braak stage of neurofibrillary degeneration associated with a tauopathy in a subject having neurofibrillary degeneration is disclosed. The method comprises the steps of (i) administering to the subject a conjugated, chelated or detectable chemical group-associated ligand that labels aggregated paired helical filament (PHF) tau protein and is capable of crossing the blood brain barrier; (ii) determining the presence and\or amount of ligand bound to extracellular aggregated PHF tau in the medial temporal lobe of the brain of the subject, and (iii) correlating the result of the determination made in (ii) with the extent of neurofibrillary degeneration in the subject. Preferred ligands include sulphonated-benzothiazole-like compounds and diamonophenothiazines.